Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Davide Pastorelli, Fable Zustovich, Giovanni Faggioni, Stefania Zovato, Martin Donach, Ornella Nicoletto, Miriam Farina, Lara Furini, Renato Ceravolo, Paolo Carli, Giuseppe Lombardi

Research output: Contribution to journalArticle

Abstract

In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.

Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalAnti-Cancer Drugs
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 2010

Keywords

  • Bevacizumab
  • Interferon
  • Renal cancer
  • Sunitinib
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this